ERBB2 and breast carcinoma: In our study, we have demonstrated that sequential administration combinatorial targeted therapy, guided by scRNA-seq, delivers a durable therapeutic efficacy in combination with ICB, leading to a prolonged stable disease of rapidly evolving HER2/neu-positive breast cancer.